Prevalence of human papillomavirus types in cervical lesions from women in rural Western India

Journal of Medical Virology

Volumn 84, Issue 7, 2012, Pages 1054-1060

  Deodhar, Kedar ^a   Gheit, Tarik ^b   Vaccarella, Salvatore ^b   Romao, Christine Carreira ^b   Tenet, Vanessa ^b   Nene, Bhagwan M ^c   Jayant, Kasturi ^c   Kelkar, Rohini ^a   Malvi, Sylla G ^c   Sylla, Bakary S ^b   Franceschi, Silvia ^b   Jeronimo, Jose ^d   Shastri, Surendra ^a   Sankaranarayanan, Rengaswamy ^b   Tommasino, Massimo ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Nargis Dutt Memorial Cancer Hospital (NDMCH)   (India)

^d Program for Appropriate Technology in Health PATH   (United States)

Author keywords

Cervical cancer; HPV prevalence; HPV vaccination; India; Multiplex PCR APEX assay

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; ARTICLE; CANCER GRADING; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 73; INDIA; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PROTEIN EXPRESSION; RURAL AREA; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CARCINOMA; FEMALE; GENOTYPE; HUMANS; INDIA; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RURAL POPULATION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRIDAE;

EID: 84860999240     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23310     Document Type: Article

References (34)

1. Basu P, Roychowdhury S, Bafna UD, Chaudhury S, Kothari S, Sekhon R, Saranath D, Biswas S, Gronn P, Silva I, Siddiqi M, Ratnam S. 2009. Human papillomavirus genotype distribution in cervical cancer in India: Results from a multi-center study. Asian Pac J Cancer Prev 10: 27-34.
2. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R. 2010. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 133: 395-406.
3. Bhatla N, Dar L, Patro AR, Kriplani A, Gulati A, Verma K, Broor S, Shah KV, Gravitt PE. 2006. Human papillomavirus type distribution in cervical cancer in Delhi, India. Int J Gynecol Pathol 25: 398-402.
4. Bhatla N, Dar L, Rajkumar PA, Kumar P, Pati SK, Kriplani A, Gulati A, Broor S, Iyer VK, Mathur S, Shah KV, Gravitt PE. 2008. Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Int J Gynecol Pathol 27: 426-430.
5. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. 2006. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24: S3-26-S3-34.
6. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El GF. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol 6: 204.
7. Dallenlenbach-Hellweg G, Trunk MJ, von Knebel Doeberitz M, 2004. Traditional and new molecular methods for early detection of cervical cancer. Arkh Patol 66: 35-39.
8. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. 2009. Clinician's guide to human papillomavirus immunology: Knowns and unknowns. Lancet Infect Dis 9: 347-356.
9. Eklund C, Zhou T, Dillner J. 2010. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 48: 4147-4155.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
11. Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, Canzian F, Tommasino M. 2006. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 44: 2025-2031.
12. Gheit T, Vaccarella S, Schmitt M, Pawlita M, Franceschi S, Sankaranarayanan R, Sylla BS, Tommasino M, Gangane N. 2009. Prevalence of human papillomavirus types in cervical and oral cancers in central India. Vaccine 27: 636-639.
13. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans IARC Monographs, Volume 90. International Agency for Research on Cancer, Lyon; 2007.
14. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128: 927-935.
15. Lu B, Kumar A, Castellsague X, Giuliano AR. 2011. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review and meta-analysis. BMC Infect Dis 11: 13.
16. National Cancer Registry Program of India. Two-year report of population based cancer registries 2004-2005. Accessed on April 3, 2011.
17. O'Neill CJ, McCluggage WG. 2006. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 13: 8-15.
18. Peedicayil A, Abraham P, Sathish N, John S, Shah K, Sridharan G, Gravitt P. 2006. Human papillomavirus genotypes associated with cervical neoplasia in India. Int J Gynecol Cancer 16: 1591-1595.
19. Pillai RM, Babu JM, Jissa VT, Lakshmi S, Chiplunkar SV, Patkar M, Tongaonkar H, Reddy KB, Chakka KN, Siddiqui M, Roychoudury S, Abraham P, Peedicayil A, Gnanamony M, Subashini J, Ram TS, Dey B, Singh N, Singh A, Jain SK, Jayshree RS. 2010. Region-wise distribution of high-risk human papillomavirus types in squamous cell carcinomas of the cervix in India. Int J Gynecol Cancer 20: 1046-1051.
20. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thorning CS. 2009. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374: 1975-1985.
21. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487-491.
22. Samarawickrema NA, Tabrizi SN, Hewavisenthi J, Leong T, Garland SM. 2011. Distribution of human papillomavirus genotypes in archival cervical tissue from women with cervical cancer in urban Sri Lanka. Int J Gynaecol Obstet 115: 180-182.
23. Sandri MT, Riggio D, Salvatici M, Passerini R, Zorzino L, Boveri S, Radice D, Spolti N, Sideri M. 2009. Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes. J Med Virol 81: 271-277.
24. Sankaranarayanan R. 2012. " See-and-treat" works for cervical cancer prevention: What about controlling the high burden in India? Ind J Med Res (In press).
25. Sankaranarayanan R, Bhatla N, Gravitt PE, Basu P, Esmy PO, Ashrafunnessa KS, Ariyaratne Y, Shah A, Nene BM. 2008. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 26: M43-M52.
26. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. 2010. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 48: 143-149.
27. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121: 621-632.
28. Schiffman M, Clifford G, Buonaguro FM. 2009. Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infect Agent Cancer 4: 8.
29. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E. 2009. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis. Cancer Treat Rev 35: 210-220.
30. Villa LL, Costa RL, Petta CA, Andrade RP, Paaavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giocoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E. 2006. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
31. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
32. Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel DM. 2007. Triage of women with ASCUS and LSIL cytology: Use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 111: 58-66.
33. Wentzensen N, von Knebel Doeberitz M. 2007. Biomarkers in cervical cancer screening. Dis Markers 23: 315-330.
34. Zerbini M, Venturoli S, Cricca M, Gallinella G, De SP, Costa S, Santini D, Musiani M. 2001. Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J Clin Pathol 54: 377-380.